Letter: Suggestions for Improving Study Design and Incorporating Virological Markers in HBV Functional Cure Research.
作者信息
Yang Chaoting, Shao Huaguo, Huang Jinsong
机构信息
The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, China.
Institute of Hepatology and Epidemiology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, China.
出版信息
Clin Transl Gastroenterol. 2025 May 16;16(8):e00847. doi: 10.14309/ctg.0000000000000847. eCollection 2025 Aug 1.
Abstract
摘要
相似文献
1
Letter: Suggestions for Improving Study Design and Incorporating Virological Markers in HBV Functional Cure Research.
Clin Transl Gastroenterol. 2025 May 16;16(8):e00847. doi: 10.14309/ctg.0000000000000847. eCollection 2025 Aug 1.
2
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis.
Hepatol Int. 2025 Jun 18. doi: 10.1007/s12072-025-10823-5.
3
Functional cure in a child with chronic hepatitis B with rtM204I mutation through an atypical serological response: a case report.
Transl Pediatr. 2025 Jul 31;14(7):1726-1732. doi: 10.21037/tp-2025-250. Epub 2025 Jul 25.
4
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
J Hepatol. 2023 Nov;79(5):1254-1269. doi: 10.1016/j.jhep.2023.06.002. Epub 2023 Jun 21.
5
HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.
Antiviral Res. 2025 Feb;234:106061. doi: 10.1016/j.antiviral.2024.106061. Epub 2024 Dec 19.
6
Serum hepatitis B virus RNA in low-level viremia of chronic hepatitis B: clinical features and association with virological response.
Virol J. 2025 May 5;22(1):132. doi: 10.1186/s12985-025-02712-y.
7
Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study.
Virol J. 2025 May 19;22(1):146. doi: 10.1186/s12985-025-02761-3.
8
Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
J Infect Dis. 2025 Jun 2;231(5):1290-1298. doi: 10.1093/infdis/jiae541.
9
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Hepatology. 2023 Nov 1;78(5):1654-1673. doi: 10.1097/HEP.0000000000000431. Epub 2023 Jun 21.
10
Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study.
EClinicalMedicine. 2025 Aug 2;87:103400. doi: 10.1016/j.eclinm.2025.103400. eCollection 2025 Sep.
本文引用的文献
1
Long-term virological and clinical evaluation of chronic hepatitis B patients under nucleos(t)ide analogues therapy.
Clin Res Hepatol Gastroenterol. 2025 Apr;49(4):102566. doi: 10.1016/j.clinre.2025.102566. Epub 2025 Mar 3.
2
Quantitative Change of Hepatitis B Surface Antigen Leading to Final Hepatitis B Surface Antigen Loss in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in China.
Clin Transl Gastroenterol. 2025 Apr 1;16(4):e00820. doi: 10.14309/ctg.0000000000000820.
3
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy.
Gut. 2024 Sep 9;73(10):1725-1736. doi: 10.1136/gutjnl-2024-332182.
4
Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy.
J Hepatol. 2016 Mar;64(3):539-46. doi: 10.1016/j.jhep.2015.10.013. Epub 2015 Oct 24.
5
Barodontalgia: in relation to scuba divers.
J Okla Dent Assoc. 1985 Spring;75(4):15-6.
Zotero 插件